Back to Search Results
Image Place holder

Jenn Logue, MD

 
Specialty: Hematology/Oncology
Program: Malignant Hematology and Cellular Therapy at Memorial Healthcare System

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Dr. Logue received her MD from Boston University School of Medicine. She completed an Internal Medicine Residency at Wake Forest School of Medicine followed by a Hematology/Oncology Fellowship at Moffitt Cancer Center/University of South Florida. Dr. Logue most recently completed a Blood and Marrow Transplant and Cellular Immunotherapy Fellowship at Moffitt Cancer Center. Dr. Logue’s specialty is Malignant Hematology with a focus on Blood and Marrow Transplant and Cellular Immunotherapy. Her clinical concentration is lymphoma and multiple myeloma, specifically with transplant and cellular therapies. Dr. Logue’s research focus is treatment with chimeric antigen receptor (CAR) T-cell therapies in lymphoma and myeloma, especially anti-CD19 CAR T-cell therapy and anti-BCMA CAR T-cell therapy. Her research interest is the assessment of treatment toxicities, late effects, and patient-reported outcomes within the realm of transplant and cell therapy.


Education & Training

Fellowship:

  • University of South Florida/Moffitt Cancer Center - Hematology/Oncology
  • Moffitt Cancer Center - Cellular Immunotherapy

Residency:

  • Wake Forest School of Medicine - Internal Medicine

Medical School:

  • Boston University School of Medicine - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Hoogland AI, Barata A, Logue J, Kommalapati A, Hyland KA, Nelson AM, Eisel SL, Small BJ, James BW, Christy SM, Bulls HW, Booth-Jones M, Jayani RV, Jain MD, Mokhtari S, Chavez JC, Lazaryan A, Shah BD, Locke FL, Jim HSL. Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2022 Jun.28(6):305.e1-305.e9. Pubmedid: 35378330. Pmcid: PMC9197947.
  • Barata A, Hoogland AI, Kommalapati A, Logue J, Welniak T, Hyland KA, Eisel SL, Small BJ, Jayani RV, Booth-Jones M, Oswald LB, Gonzalez BD, Kirtane KS, Jain MD, Mokhtari S, Chavez JC, Lazaryan A, Shah BD, Locke FL, Jim HSL. Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. Transplant Cell Ther. 2022 Jul.28(7):401.e1-401.e7. Pubmedid: 35580732. Pmcid: PMC9339228.
  • Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec.6(24):6109-6119. Pubmedid: 35939783. Pmcid: PMC9768247.
  • Logue JM, Chavez JC. How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure. CURR TREAT OPTION ON. 2021 Oct.22(12):112. Pubmedid: 34697650.
  • Barata A, Hoogland AI, Hyland KA, Otto AK, Kommalapati A, Jayani RV, Irizarry-Arroyo N, Collier A, Rodriguez Y, Welniak TL, Booth-Jones M, Logue J, Small BJ, Jain MD, Reblin M, Locke FL, Jim HSL. Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy. Psychooncology. 2021 Aug.30(8):1294-1301. Pubmedid: 33739548. Pmcid: PMC9828891.
  • Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, Grillo G, Cao B, Kim J, Chavez JC, Baluch A, Khimani F, Lazaryan A, Nishihori T, Liu HD, Pinilla-Ibarz J, Shah BD, Faramand R, Coghill AE, Davila ML, Dholaria BR, Jain MD, Locke FL. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021 Apr.106(4):978-986. Pubmedid: 32327504. Pmcid: PMC8017820.
  • Soike MH, Logue J, Qasem S, Hughes RT, McTyre E, Su J, Triozzi P, Bendandi M, Lo HW, Ahmed T, O'Neill SS, Debinski W, Pasche B, Watabe K, Miller LD, Chan MD, Ruiz J. CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgery. Sci Rep. 2019 Oct.9(1):14385. Pubmedid: 31591443. Pmcid: PMC6779906.
  • Shah BA, Qureshi MM, Logue JM, Cooley TP, Zaner KS, Jalisi S, Truong MT. Assessing cumulative acute toxicity of chemoradiotherapy in head and neck cancer with or without induction chemotherapy. Am J Otolaryngol. 2018 May.38(4):456-461. Pubmedid: 28427799.
  • Logue JM, Kiani B, Bitting RL. Pazopanib and Statin-Induced Rhabdomyolysis. Case Rep Oncol. 2017 Oct.10(3):954-957. Pubmedid: 29279698. Pmcid: PMC5731169.
  • Ahn Y, Sims C, Logue JM, Weatherbee SD, Krumlauf R. Lrp4 and Wise interplay controls the formation and patterning of mammary and other skin appendage placodes by modulating Wnt signaling. Development. 2013 Feb.140(3):583-593. Pubmedid: 23293290. Pmcid: PMC6514302.

Patient Comments
Overall Satisfaction
0
★★★★★
★★★★★

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments